Pluristem Therapeutics (PSTI +3.3%) forges a partnership with Cha Bio&Diostech for using...


Pluristem Therapeutics (PSTI +3.3%) forges a partnership with Cha Bio&Diostech for using Pluristem's PLX stem-cell therapy to develop treatments for peripheral artery disease (PAD) in South Korea, where 1M people suffer from the problem. Once the first PLX product is approved in the country, the companies will form a JV to commercialize it. As part of the deal, Pluristem will issue Cha 2.5M shares in return for 1.01M shares of Cha, reflecting a consideration of $10M for the Pluristem stock. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs